The binding of TK1 monoclonal antibodies to their corresponding TK1 epitopes was observed in all cancer cell models but not in normal lymphocytes suggesting the suitability of anti-TK1 antibodies as a highly specific targeting approach in malignant cells. Here, TK1 is linked to cancer.